1,721,432 research outputs found
Establishment of the 1st World Health Organization International Standard for Plasmodium falciparum DNA for nucleic acidamplification technique (NAT)-based assays
No full textBackground: In order to harmonize results for the detection and quantification of Plasmodium
falciparum DNA by nucleic acid amplification technique (NAT)-based assays, a World Health
Organization (WHO) collaborative study was performed, evaluating a series of candidate standard
preparations.
Methods: Fourteen laboratories from 10 different countries participated in the collaborative
study. Four candidate preparations based upon blood samples parasitaemic for P. falciparum were
evaluated in the study. Sample AA was lyophilized, whilst samples BB, CC and DD were liquid/
frozen preparations. The candidate standards were tested by each laboratory at a range of dilutions
in four independent assays, using both qualitative and quantitative NAT-based assays. The results
were collated and analysed statistically.
Results: Twenty sets of data were returned from the participating laboratories and used to
determine the mean P. falciparum DNA content for each sample. The mean log10 "equivalents"/ml
were 8.51 for sample AA, 8.45 for sample BB, 8.35 for sample CC, and 5.51 for sample DD. The
freeze-dried preparation AA, was examined by accelerated thermal degradation studies and found
to be highly stable.
Conclusion: On the basis of the collaborative study, the freeze-dried material, AA (NIBSC code
No. 04/176) was established as the 1st WHO International Standard for P. falciparum DNA NATbased
assays and has been assigned a potency of 109 International Units (IU) per ml. Each vial
contains 5 × 108 IU, equivalent to 0.5 ml of material after reconstitution
RIvaroxaban and VAscular Surgery (RIVAS): insights from a multicenter, worldwide web-based survey
No full textN/
The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment
Get PDFPURPOSE: The aims of the TP53 Colorectal Cancer (CRC) International Collaborative Study were to evaluate the possible associations between specific TP53 mutations and tumor site, and to evaluate the prognostic and predictive significance of these mutations in different site, stage, and treatment subgroups.
PATIENTS AND METHODS: A total of 3,583 CRC patients from 25 different research groups in 17 countries were recruited to the study. Patients were divided into three groups according to site of the primary tumor. TP53 mutational analyses spanned exons 4 to 8.
RESULTS: TP53 mutations were found in 34% of the proximal colon tumors and in 45% of the distal colon and rectal tumors. They were associated with lymphatic invasion in proximal tumors. In distal colon tumors, deletions causing loss of amino acids were associated with worse survival. In proximal colon tumors, mutations in exon 5 showed a trend toward statistical significance (P < .05) when overall survival was considered. Dukes' C tumors with wild-type TP53 and those with mutated TP53 (proximal tumors) showed significantly better prognosis when treated with adjuvant chemotherapy.
CONCLUSION: Analysis of TP53 mutations from a large cohort of CRC patients has identified tumor site, type of mutation, and adjuvant treatment as important factors in determining the prognostic significance of this genetic alteration
Patient compliance and therapeutic coverage: amlodipine versus nifedipine SR in the treatment of hypertension and angina: interim results
No full textCollaborative study to evaluate a candidate World Health Organization international standard for chikungunya virus for nucleic acid amplification technique (NAT)-based assays
Get PDFCollaborative Study Group - Portugal:Maria João Alves, Líbia Zé-Zé (National Institute of Health Dr. Ricardo Jorge, Center for Vectors and Infectious Diseases Research)This report describes the World Health Organization (WHO) project to develop an international
standard (IS) for Chikungunya virus (CHIKV) RNA for use with nucleic acid amplification
technique (NAT)-based assays. An international collaborative study was conducted to determine the
potency of the candidate standard using a range of NAT-based assays for CHIKV, and to evaluate
the suitability of the candidate for the calibration of secondary reference materials and the
standardization of CHIKV viral load measurements.
The candidate standard consisted of a heat inactivated CHIKV strain of the East/South/Central
African genotype (ESCA), also known as the Indian Ocean Lineage, isolated from a patient
returning from India to the United States in 20061
, diluted in human negative plasma. The
lyophilized candidate preparation (Sample 1), the corresponding liquid-frozen bulk material (Sample
2) and three different clinical samples (Sample 3, Sample 4 and Sample 5) were included in the
collaborative study. Twenty-five laboratories representing 14 countries participated in the study to
evaluate the material using their routine CHIKV NAT assays. Twenty-four laboratories returned 31
data sets from 17 commercial assays and 14 in-house methods. Of these 31 methods, 11 were
quantitative and 20 were qualitative.
The results of the study indicate the suitability of the candidate material of the CHIKV strain of
ESCA genotype (Sample 1) as the proposed 1st WHO IS for CHIKV. It is therefore proposed that
the candidate material (PEI code 11785/16) is established as the 1st WHO IS for CHIKV RNA for
NAT-based assays with an assigned potency of 2,500,000 International Units (IU)/mL when
reconstituted in 0.5 mL of nuclease-free water.
On-going studies for real-time and accelerated stability of the proposed IS indicate that the
preparation is stable and suitable for long-term use under the proposed storage conditions.info:eu-repo/semantics/publishedVersio
Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes
No full text
Early experience with laparoscopic lavage for perforated diverticulitis
No full textBACKGROUND: Laparoscopic lavage has recently emerged as a
promising alternative to sigmoid resection in the treatment of
perforated diverticulitis. This study examined an early
experience with this technique. METHODS: The files of all
patients with complicated diverticulitis were searched in 34
teaching hospitals of the Netherlands. Patients with perforated
diverticulitis treated with laparoscopic lavage between 1
January 2008 and 31 December 2010 were included. RESULTS:
Treatment with laparoscopic lavage was performed in only 38
patients in ten hospitals. Lavage was successful in controlling
sepsis in 31 of the 38 included patients, with 32 per cent
morbidity (10 of 31 patients) and fast recovery. Overall, 17 of
38 patients developed complications, of whom two had a missed
overt sigmoid perforation. Two patients died from multiple organ
failure and one from aspiration pneumonia; one other patient
died after palliative management of inoperable lung carcinoma.
Three patients in whom lavage was successful underwent
subsequent sigmoid resection for recurrent diverticulitis.
Patients in whom lavage was unsuccessful tended to have more
co-morbidities, a higher preoperative C-reactive protein
concentration and a higher Mannheim Peritonitis Index.
CONCLUSION: Laparoscopic lavage for perforated diverticulitis
was feasible in the majority of patients, but identification of
an overt sigmoid perforation and patient selection are of
critical importance
The Italian Group for LAP-BAND: predictive value of initial body mass index for weight loss after 5 years of follow-up
No full text- …
